Status:
COMPLETED
Study Evaluating the Safety and Tolerability of NSA-789
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive ...
Eligibility Criteria
Inclusion
- Inclusion:
- Healthy men and women between 18 and 50 years old.
- Women must be of non-child-bearing potential (not able to have children).
- Must be of normal body weight.
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00633048
Start Date
March 1 2008
End Date
May 1 2008
Last Update
February 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tacoma, Washington, United States, 98418